Sanofi SA (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 182   

Articles published

SNY 38.54 +0.17 (0.44%)
price chart
Could Sanofi SA (ADR) Crash Even More? The Stock Just Made 52-Week Low
The stock of Sanofi SA (ADR) (NYSE:SNY) hit a new 52-week low and has $36.57 target or 5.00% below today's $38.49 share price.
Analyst's Report Recap: Sanofi SA (ADR)
The shares of Sanofi SA (ADR) (NYSE:SNY) currently has mean rating of 2.33 while 1 analysts have recommended the shares as “BUY”, 0 recommended as “OUTPERFORM” and 2 recommended as “HOLD”.
Anticipated EPS Decrease for Sanofi SA (ADR) (SNY)
Sanofi SA (ADR) Just Recorded A Sigfniciant Gap Down  Sonoran Weekly Review
Sanofi SA (ADR) Scouts For New Cancer Treatments That Harness Immune Cells
Pharmaceutical giant Sanofi is partnering with two biotech companies -- Evotec AG in Hamburg, Germany, and Apeiron Biologics AG in Vienna, Austria - in its latest effort to develop a drug that harnesses the body's own immune system in the fight against ...
Can Sanofi and Others Stop Zika?
Sanofi SA (ADR) (NYSE:SNY) has started a development program to contain the Zika virus. The virus was discovered in Africa in 1947.
Regeneron Pharmaceuticals Inc And Sanofi SA (ADR) Win EU Nod For Cholesterol ...
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), a leader in the biotech sector, and Sanofi SA (ADR) (NYSE:SNY), the French pharmaceutical giant, have fetched a victory adding to their success in the pharmaceutical sector.
Company Update (NASDAQ:REGN): Regeneron Pharmaceuticals Inc and Sanofi SA ...  Smarter Analyst
Sanofi SA (ADR) And Regeneron's $2.2B Pursuit Of Immuno-Oncology Drugs Is Late ...
Sanofi Regeneron Pharmaceuticals Inc. and Sanofi announced a $2.2 billion collaboration on Tuesday in which the drug companies will pursue cancer treatments that pit the body's own immune system against tumors.
Sanofi SA And Regeneron Pharmaceuticals Extend Partnership In Cancer Treatments  Bidness ETC
Canaccord Reiterates Buy on Regeneron Pharmaceuticals Inc (REGN) Following ...  Smarter Analyst
Who will acquire Relypsa: Merck and Co or Sanofi SA?
Soon after, the Financial Times ran a slightly different story. Reporting from sources, it said Relypsa was itself preparing for a sale, and drug-makers like GlaxoSmithKline plc (ADR) (NYSE:GSK), Sanofi SA and Switzerland's Galenica might be possible ...
EXCLUSIVE: Relypsa Being Evaluated By 3-4 Potential Acquirers; Sanofi Seen ...  Benzinga
Google Inc, Sanofi SA (ADR) Partner Up For Diabetes Research
The Wall Street Journal has reported that Google Inc. (NASDAQ:GOOG) is going to partner up with European pharmaceutical giant Sanofi SA (NYSE:SNY) to research on monitoring and curing diabetes. While both the companies refused to disclose how ...
Sanofi Teams Up with Google Life Sciences for Diabetes
Google, Sanofi join forces on Diabetes monitoring and treatment  MarketWatch
Sanofi Joins Race to Develop Zika Vaccine
Sanofi SA (ADR) (NYSE:SNY) has launched its vaccine development program for the rapidly spreading Zika virus. The virus was first detected in May 2015 in Brazil, and has since spread to almost 25 countries and territories in the Americas.
Sanofi SA (ADR) Chief Strategy Officer Resigns; Company Facing Another Turmoil ...
Sanofi SA (ADR) (NYSE:SNY), the French pharmaceutical giant, is facing another turmoil as its chief strategy officer, David-Alexandre Gros, has resigned only six months after the company's famous chief executive officer, Chris Viehbacher, was ousted by ...